DARE BIOSCIENCE INC (DARE) Stock Overview
NASDAQ:DARE - US23666P2002 - Common Stock
DARE Key Statistics, Chart & Performance
The current stock price of DARE is 2.09 USD. In the past month the price increased by 5.39%. In the past year, price decreased by -37.13%.
DARE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.8 | 684.82B | ||
| JNJ | JOHNSON & JOHNSON | 17.8 | 428.67B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.12 | 249.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.47 | 247.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.85 | 240.61B | ||
| MRK | MERCK & CO. INC. | 10.8 | 207.77B | ||
| PFE | PFIZER INC | 7.22 | 139.10B | ||
| SNY | SANOFI-ADR | 10.41 | 112.69B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.82 | 93.44B | ||
| GSK | GSK PLC-SPON ADR | 8.75 | 79.71B | ||
| ZTS | ZOETIS INC | 24.36 | 67.14B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 52.14 | 47.75B |
Related stock screener links
About DARE
Company Profile
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Company Info
DARE BIOSCIENCE INC
3655 Nobel Dr Ste 260
San Diego CALIFORNIA 92122 US
CEO: Sabrina Martucci Johnson
Employees: 22
Phone: 18589267655
DARE BIOSCIENCE INC / DARE FAQ
What is the stock price of DARE BIOSCIENCE INC today?
The current stock price of DARE is 2.09 USD. The price decreased by -2.79% in the last trading session.
What is the ticker symbol for DARE BIOSCIENCE INC stock?
The exchange symbol of DARE BIOSCIENCE INC is DARE and it is listed on the Nasdaq exchange.
On which exchange is DARE stock listed?
DARE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DARE BIOSCIENCE INC stock?
10 analysts have analysed DARE and the average price target is 11.9 USD. This implies a price increase of 469.38% is expected in the next year compared to the current price of 2.09. Check the DARE BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DARE BIOSCIENCE INC worth?
DARE BIOSCIENCE INC (DARE) has a market capitalization of 28.17M USD. This makes DARE a Nano Cap stock.
How many employees does DARE BIOSCIENCE INC have?
DARE BIOSCIENCE INC (DARE) currently has 22 employees.
What are the support and resistance levels for DARE BIOSCIENCE INC (DARE) stock?
DARE BIOSCIENCE INC (DARE) has a support level at 2.07 and a resistance level at 2.16. Check the full technical report for a detailed analysis of DARE support and resistance levels.
Is DARE BIOSCIENCE INC (DARE) expected to grow?
The Revenue of DARE BIOSCIENCE INC (DARE) is expected to grow by 419.65% in the next year. Check the estimates tab for more information on the DARE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DARE BIOSCIENCE INC (DARE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DARE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DARE, evaluating the profitability, health, valuation and growth aspects
- DARE BIOSCIENCE INC (DARE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DARE BIOSCIENCE INC (DARE) Sales and EPS estimates to see what analysts future expectations are.
- DARE BIOSCIENCE INC (DARE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DARE BIOSCIENCE INC (DARE) Insider and Institutional Ownership to learn about the owners and their transactions.
- DARE BIOSCIENCE INC (DARE) Stock Chart to make your own analysis
- DARE BIOSCIENCE INC (DARE) Latest news and press-releases to stay up to date.
Does DARE BIOSCIENCE INC (DARE) stock pay dividends?
DARE does not pay a dividend.
When does DARE BIOSCIENCE INC (DARE) report earnings?
DARE BIOSCIENCE INC (DARE) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of DARE BIOSCIENCE INC (DARE)?
DARE BIOSCIENCE INC (DARE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.15).
What is the Short Interest ratio of DARE BIOSCIENCE INC (DARE) stock?
The outstanding short interest for DARE BIOSCIENCE INC (DARE) is 1.96% of its float. Check the ownership tab for more information on the DARE short interest.
DARE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DARE. When comparing the yearly performance of all stocks, DARE is a bad performer in the overall market: 94.11% of all stocks are doing better.
DARE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DARE. DARE has a bad profitability rating. Also its financial health evaluation is rather negative.
DARE Financial Highlights
Over the last trailing twelve months DARE reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -91.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
DARE Forecast & Estimates
10 analysts have analysed DARE and the average price target is 11.9 USD. This implies a price increase of 469.38% is expected in the next year compared to the current price of 2.09.
For the next year, analysts expect an EPS growth of -289.37% and a revenue growth 419.65% for DARE